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1. Introduction
Traumatic brain injury (TBI) is a devastating and complex disease state. Of the observed
complications associated with TBI, the development of seizures following injury can be among
the most challenging to manage. In addition to the direct effects on the brain, seizures following
TBI lead to significant patient morbidity, with potential limitations on overall independence.
Quality-of-life may also be adversely affected as the diagnosis of seizure carries the burden of
extended exposure to anti-epileptic drugs. The use of these therapies often entails unfavorable
medication related side-effects, frequent laboratory monitoring and dosage adjustments, as
well as frequent physician visits. With these factors in mind, identification and prophylaxis of
those at risk for post-traumatic seizures may provide significant improvement on patient
outcomes.
2. Historical perspective
The association between head injury and seizures has long been observed. In the Hippocratic
text, “On Injuries of the Head”, wounds to the left temporal region were described as being
associated with convulsion on the right side of the body. Later, Hippocratic surgeons noted
that convulsions following head trauma were often a sign of impending fatality. [1] Interest‐
ingly, the reference to seizures was only in the immediate time frame surrounding the injury;
chronic seizures were not noted to have been documented in those writings. [2] As medicine
and neuroscience progressed, the recognition of the association between head trauma and the
development of seizure disorder gradually began to grow. As an example, in the 14th century,
the Italian physician Valescus de Tharanta described a patient who suffered a penetrating head
wound which infiltrated into the pia mater and subsequently experienced seizures 7 to 8 times
a day until death. [3] Approximately 150 years later, Berengarius da Carpi, an Italian physician
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and surgeon, documented that epileptic seizures developed approximately 60 days following
a severe head wound which likely is the first documentation of post-traumatic epilepsy, or
seizures occurring outside of the immediate post-injury period. This association was further
strengthened by the writing of Duretus who reports his observations of a patient suffering a
depressed skull fracture who developed seizures 6 years following injury. [1]
Despite the above observations, head injury failed to gain recognition as a common cause of
epilepsy. Perhaps the first major medical publication noting this connection was book “Epilepsy
and Its Treatment” in 1904 in which its author William Spratling specifically mentions trauma
as an etiology for epilepsy. Spratling writes, “Traumatic lesions of the cranium and the
cerebrum cause epilepsy without any predisposition to the disease”, and he goes on to describe
observed epileptic patterns in significant detail. [4]
The majority of our modern knowledge pertaining to seizures following TBI is derived from
military literature. The Second World War, the Korean conflict, and the Vietnam War offered
an extensive cohort from which to observe the effects of head trauma. While this data has
provided tremendous insight, it does not translate well to head injuries in the civilian sector
in regard to mechanism and potential complications. Recently, epidemiologic investigations
have examined the impact of TBI and the frequency of post-traumatic seizures in civilians,
yielding valuable information for this very different patient population.
3. Definitions
Post-traumatic seizure disorder is a broad term for new-onset seizures following TBI. This
terminology fails to capture the distinct differences in etiology, incidence, outcome, and
management of these seizures. It is these differences that necessitated the development of a
classification system, separating the observed seizures into distinct diagnostic entities based
on time of development. The first formal classification of post-traumatic seizures was sug‐
gested in 1939 when Elvidge proposed the observed seizures be separated into 3 distinct
groups: immediate (within the first few hours following injury), delayed (occurring with 2
weeks of injury), and late (those occurring after a period of time). He further proposed that
the immediate and delayed seizures be combined into a group of events termed early epilepsy
which was felt to be distinctly different from late epilepsy. [5] This classification has been
modified slightly, yet generally remains accepted to this day. The current accepted definitions
adopted into practice today are:
• Immediate seizure: Seizures occurring less than 24 hours post injury.
• Early seizures: Seizures occurring less than 1 week post injury.
• Late seizure: Seizures occurring greater than 1 week post injury. [2] These seizures are
considered “unprovoked” and are therefore considered epileptic in nature.
• Post-traumatic epilepsy: Recurrent late seizures, with no identifiable cause other then TBI
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4. Epidemiology
The burden of post traumatic seizures (PTS) is often underestimated in relation to the overall
incidence of epilepsy. A prevalence study by Hauser et al examined several characteristics of
epileptic patients in Rochester, MN. Their results showed that approximately 20% of symp‐
tomatic disease and 5% of all epilepsies can be attributed to traumatic injury and that in patients
less than the age of 65, brain trauma was the most frequently identified risk factor associated
with the development of epilepsy. [6] In fact, trauma may be the primary cause of epilepsy in
up to 30% of patients between the ages of 15 and 34. [2]
The incidence of seizures following TBI is commonly separated into two distinct categories;
early seizures (occurring within 1 week of the index injury) and late (occurring greater than 1
week after the index injury). Each of these categories varies from the other in terms of incidence
and risk factors.
The first major publication documenting the incidence of early PTS was presented in 1960. Jennett
et al found that among 898 patients admitted with closed head injury, 4.2% experienced seizure
within the first 7 days following the injury. [7] Approximately 20 years later, in a retrospective
chart review of 2,747 head injury patients experiencing loss of consciousness, Annegers et all
found the incidence of early seizure was 2.1%, and of those, 75% occurred in the first 24 hours
following injury. [8] Desai et al reviewed the records of 702 patients with any degree of head
trauma and found early seizure occurred in 4.1% of patients. [9] Annegers published a second
retrospective chart review in 1998 after examining the records of 4,541 pediatric and adult head
injury patients. This in-depth review reported the incidence of early PTS to be 2.6%. [10] Asikainen
examined a group of 490 TBI patients (approximately 50% of patients studied were under the
age of 16) admitted to a TBI rehabilitation facility. Early PTS were observed at an incidence of
16.4%, a number higher than what had been observed previously. The authors comment that
there was a statistically significant relationship between the age at time of injury and occur‐
rence of early PTS, as they reported that patients age 7 or younger experience early seizures at a
rate of 30.8%, those ages 8 to 16 at a rate of 20%, and patients above the age of 16 at a rate of 8.4%.
[11] These results mirrored findings in earlier studies in which pediatric head injury patients
were more likely to experience early seizure, independent of the degree of head trauma as
compared to adult patients with similar injuries. [7, 8]
Military data is the best source of information when assessing seizure risk following pene‐
trating head injury. The Vietnam Head Injury Study (VHIS) provided valuable information
regarding outcomes of patients with penetrating head wounds, including incidence of seizure.
In this cohort, early PTS was observed at 4.3%. [12, 13]
While these studies offer useful insight into overall frequency of early PTS, there are limitations
that must be addressed. The heterogeneity of the populations being assessed in the available
literature makes generalization difficult. In the reports mentioned above, the characteristics of
patients observed varies drastically based on severity of head injury, age distribution of the
population observed, and mechanism of injury. In addition, the standard of care provided to
the head injury patient has evolved and should be considered when assessing the occurrence
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of any disease sequelae. It must be noted that very little is mentioned in the epidemiologic
literature about therapies provided to these patients. When evaluating the overall incidence
of early PTS, these limitations must be taken into consideration.
Despite the above mentioned limitations, some of the most useful data gained from these
epidemiologic studies is the identification of risk factors for early PTS. When looking at these
risk factors as a whole and considering the various populations evaluated, several factors stand
out. Age at the time of injury is associated with risk of early PTS, as younger patients are more
likely to experience this complication than older patients. Jennett, as stated above, found that
patients < 5 years of age were at increased risk of early PTS at any degree of head injury. Of
the 75 patients in this age demographic, 9.4% developed early PTS while patients older than
the age of 5 had in incidence rate of 3.8%. [7] Annegers et al. also identified children as being
at higher risk of early PTS. The incidence of early PTS in patients <15 years of age was 30%
while the rate was 10% in adult patients. [8] Similarly, Desai and Asikainen also found that
younger patients had a greater risk of early PTS compared with older patients. [9, 11]
Severity of injury at the time of presentation has also been repeatedly associated with increased
risk of early PTS. Early on, duration of post-traumatic amnesia (PTA), a guide to assessing the
degree of brain injury as reported by Jennett, was found to be associated with an increased
risk of early PTS. Approximately 11.7% of patients with PTA lasting greater than 24 hours were
seen to have early PTS while those with shorter durations experienced early seizures at a rate
of 2.7%. [7] Desai reported that focal deficit on admission and loss of consciousness
(LOC)/PTA of more than 30 minutes following injury greatly increased the likelihood of early
PTS. [9] It has also been shown that patients presenting with Glascow Coma Scale (GCS) scores
of <10 have an increased risk of early PTS with an incidence as high as 20%. [14] Lee et al and
Gilad et al examined the rates of PTS following mild head injury and found no increased
incidence of seizure development than in the general population experiencing non-trauma
related seizures further supporting the theory that severe head injuries pose a higher risk for
PTS development. [15, 16] Skull fracture and penetrating head injury have been repeatedly
shown to increase the risk of early PTS. Basilar skull fractures, specifically those that are
depressed or in the temporal-parietal region, appear to infer the highest risk. [7, 9]
The presence of intracranial blood on radiographic imaging has also been positively associated
with early PTS. It is observed that intracranial hemorrhage (ICH) may precede early PTS in up
to 23% of patients while epidural/subdural hematoma and cortical contusion are seen in
approximately 16% of such cases. [9, 14] Jennett utilized the presence of bloodstained cerebral
spinal fluid (CSF) to infer the presence of ICH as cranial imaging at the time was very limited.
In those with bloodstained CSF, early PTS were observed at a rate of 9.7% which is noted to
be approximately double the incidence of patients observed in the entire series. [7] Addition‐
ally, a survey of approximately 3000 patients with severe closed head injury revealed that ICH
was present in 66% of all patients experiencing early PTS. [17]
The incidence and risk factors for late PTS are significantly different than that of early PTS and
must be described separately. The lowest incidence of late PTS reported was by Jennett at 10.2%
whereas Caveness et al, in the VHIS, reported a rate of 27.9%. [7, 13] Annengers, having
collected data on 2,747 patients, was able to compare the incidence of late PTS to the expected
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rate of new onset epilepsy. Using the age and sex-specific incidence rates for Rochester,
Minnesota as a comparator, there was found to be a 3.6 fold increase in the risk of developing
seizure disorder following head trauma. [8]
Several authors have assessed the duration of risk for the onset of late PTS and a strong trend
has emerged from that data. The time-frame for the development of late PTS potentially
extends several years post-injury. Salazar et al, utilizing data from the VHIS, found that 7% of
all patients with late PTS reported their first seizure 10 or more years post injury while
Annegers reports that in patients with moderate to severe TBI, the risk for late PTS extends as
far as 20 years post injury. [10, 12] With the awareness of the extended risk for late PTS, it must
be noted that more than half of all seizures occur within the 1 year following TBI and approx‐
imately 80% occurring within 2 years. [7, 12, 13, 18, 19]
Early PTS are found to be an important predictor of late PTS as Jennett reports a four-fold
increase in late PTS if the patient seizes within 7 days of injury. [7] Annengers also found that
in patients with moderate or severe TBI, early PTS were associated with an increased likelihood
of late PTS. This was found not to be true in pediatric patients, mirroring the findings of
Asikainen, who reported increasing age as predisposing factor for late onset seizures. [8, 11]
Temkin and Englander report that the presence of intracranial blood, be that SDH or ICH,
increases the risk of late seizure development some 400 times the expected rate seen in the
general population. [14] Several investigators also report the severity of head injury, as
stratified by GCS or an extended duration (most commonly > 24 hours) of PTA, exhibits a
positive correlation with late PTS. [7, 10, 11, 13, 14, 19, 21]
Study Author Population N EarlySeizure % Risk Factors Identified
Late Seizure
% Risk Factors Identified
Jennett and Lewin 7 All admittedpatients 896 4.2
Age<5, PTA >24 hours,
skull fracture, ICH 10.2
Early PTS, PTA >24 hours,
Depressed Skull fracture
Annengers et al. 1980 8 Generalpopulation 2747 2.1 Age <15, severe injury 1.9 Moderate/ Severe TBI
Desai et al. 9 All admittedpatients 702 4.1
Age <16, focal defecit,
LOC/ PTA >30 minutes,
skull fracture, ICH
Not assessed Not assessed
Annegers et al. 1998 [10] Gerneralpopulation 4541 2.6 Not assessed 2.1
Early PTS, Cortical
Contusion/ SDH, PTA
>24hours
Asikainen et al. [11] TBI Rehab 490 16.4 Age <8 24.8 Coma >24 hours
Englander et al. [20] Severe TBI 647 3 Not Assessed 10.2
Early PTS, cortical
contusion, dural
penetration, multiple
intracranial procedures,
>5mm midline shift,
evacuated SDH
Table 1. Incidence and Risk Factors for PTS
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Early Late
• Penetrating Head Injury • Early PTS
• Age <16 years • Advanced Age
• Severity of injury (GCS <10) • Intracranial Blood
• Basilar Skull Fracture • Severity of Injury
• Intracranial Blood
Table 2. Risk Factors for PTS
5. Pathophysiology
The exact mechanisms surrounding the pathogenesis of PTS are still highly debated. Despite
extensive animal modeling and basic science bench work, an accurate replication of human
TBI has yet to be created. With the lack of an accurate model, the hypotheses found regarding
PTS development must be taken in such context. [22]
The pathology surrounding the development of PTS is likely different based on the time of
seizure onset, with different mechanisms playing a role in the development of early PTS and
late PTS. Early PTS are often considered injury-induced or “provoked” and therefore cannot
be considered epileptic. Following the initial insult of tissue deformation and compression, a
cascade of events begins to take place almost immediately. Vascular damage and increased
permeability of the blood brain barrier (BBB) are noted. [22, 23] Inflammatory cascades are
drastically up-regulated leading to neuronal and glial swelling. Glial swelling may lead to
impaired neuronal oxygen delivery and subsequent energy depletion leading to cellular death.
Glutamate, an excitatory neurotransmitter, is released in high quantities. High concentrations
of extracellular glutamate may stimulate ion channel activation and an intracellular flooding
of calcium, followed by eventual cell death. [22, 23, 24] In any type of penetrating injury, direct
neuronal damage due to cortical laceration, contusion, imbedded bone fragments, or retained
foreign bodies becomes extraordinarily irritating to the injured brain and a potential focus for
seizure activity. Also, the presence of intracranial blood has been found to predispose the TBI
patient to early PTS. When extravasated blood undergoes hemolysis, hemoglobin is engulfed
by macrophages which degrade the hemoglobin into hemosiderin and biliverdin. Hemosi‐
derin is deposited into neuronal tissue. These pathogenic deposits initiate lipid peroxidation,
damaging cell membranes, and inhibiting Na-K ATPase. [25, 26] The combination of these
factors is profoundly pro-excitatory and likely predisposes the post TBI patient to seizures
proximal to the time of injury.
The pathology of late PTS is considerably different and more controversial. There are three
core theories of epileptogenesis in this setting, the kindling model, the fluid-percussion model,
and the synaptic plasticity model. Each of these models attempts to describe the changes taking
place in the brain during the latent period between the time of injury and onset of first late
seizure.
Traumatic Brain Injury172
The kindling theory of epileptogenesis is well validated in several animal models. Briefly, weak
electrical stimulation is applied to specific, susceptible regions of the brain in rodents until a
seizure occurrs. It has been found that over time, less stimulation was needed to initiate a
seizure and this reduced threshold is a change that appears permanent over the remaining life
of the animal. In the post-TBI human brain, it is thought that subclinical seizures due to
structure changes or brain lesions will reduce the seizure threshold to a point in which
epileptogenesis occurs. [27, 28] While this is well described in several animal models, the
findings do not completely translate into human patients. Additionally, compounds tradi‐
tionally assumed effective in controlling kindling type epilepsy (phenytoin, carbamazapime)
have been shown to be ineffective preventing late PTS. [29]
The fluid-percussion model may more accurately help depict epileptogensis following TBI in
humans. In animal-based experiments, a small hole is drilled into the skull of the animal,
followed by the delivery of a fluid-wave percussion against the intact dura initiated by a
pendulum impact on a fluid column. The seizures following this type of injury appear after a
latent period, much like is seen in late PTS. Sustained hyperexcitablity was also observed in
the region surrounding the injured neocortex and this excitability was associated with intense
glial reactivity. [30] This reactivity may impair glutamate metabolism, exposing injured
neurons to potentially toxic concentrations of this excitatory neurotransmitter. [31] This also
mirrors late PTS in humans, as epileptiform activity seems to generate from the injured,
hyperexcitable region of brain. [30]
The brain has the ability to adapt to injury through both changes in function and structural re-
organization. [32, 33, 34] These changes are termed synaptic plasticity and are found to be an
adaptive mechanism aiding in neurologic recovery. [35] During the recovery process, com‐
pensatory axons sprout, forming new adaptive neural pathways. While generally beneficial
to recovery, these sprouts may, in some settings, become a focus for epileptic activity and may
allow a seizure to impact relatively distant regions of the brain. [36] This “maladaptive
plasticity” after TBI makes management of this potential pathology very challenging as not all
plasticity is harmful. In using therapies that target the sprouting axons, there may be significant
impairment in neurological recovery as “adaptive plasticity” would be targeted as well. [37, 38]
6. Impact
Post-traumatic seizures have a broad, sweeping impact on the lives of post-TBI patients. In
addition to loss of independence from seizure restrictions (restricted driving privileges);
psychological health, employment, quality of life, and mortality may also suffer.
Recurrent seizures are identified as an important cause of hospital readmission among patients
with severe TBI. [39, 40] These readmissions are not always directly related to PTS as psycho‐
logically related admissions are seen to increase as well. It is understood that TBI patients often
suffer from mood disturbances and behavioral abnormalities. Patients with PTS are increas‐
ingly sensitive to these disorders and there is a significant increase in the number of psychiatric
related hospitalizations among patients with PTS as compared to those without. [41] Addi‐
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tionally, it has been found that irritability and aggressive, disinhibited behavior were observed
to be more frequent and severe in rehabilitation patients with PTS as opposed to those not
experiencing seizures. [41]
Post-traumatic seizures have been found to correlate with poorer outcomes and quality of life.
In the VHIS, seizures following penetrating head injury were 1 of 7 impairments that were
independently predictive of poor employment status. [42] Also, Asikainen reports that patients
with PTS have inferior outcomes per Glasgow Outcome Scale (GOS) scores when compared
to those without PTS. These results were mirrored by the findings of Mazzini, who also notes
that PTS correlated with poorer GOS scores as well as several other neurobehavioral scales in
TBI patients 1 year post injury. [11, 43]
Mortality is seen to be higher in patients with PTS in multiple reports, although it is unknown
if there is a direct correlation. [44, 45, 46, 47] It is highly possible that the increase in the
incidence of death is more likely related to the severity of the injury as opposed to the
development of seizures. [48, 49]
7. Prevention of post-traumatic seizures
With the evolution of the association between head injury and seizure activity, as well as the
recognition of the above discussed repercussions, came considerable efforts to develop
preventative strategies against epileptic activity post TBI. Early studies, some dating back to
the late 1940’s, examined the use of anti-epileptic medication in patients with a variety of head
injuries. Rapport and Penry noted that in three distinct series of head injured patients, the use
of anti-epileptic medication seemed to reduce the incidence of seizure activity when compared
to those not receiving such treatment. Their survey of American board certified neurosurgeons
found that, at the time, only 14% of those polled typically used PTS prophylaxis. There were
no specific professional recommendations for prophylactic treatment and most physicians at
the time felt the evidence was considerably sparse. In fact, the most common reasoning for not
treating prophylactically was uncertainty of appropriate indication for treatment. When a PTS
prophylaxis regimen was initiated, the use of diphenylhydantoin was by far the most com‐
monly used medication, followed the combination of phenobarbitol + diphenylhydantoin. [50]
Phenytoin, the most commonly utilized agent in the hydantoin class, is the most extensively
studied PTS prophylaxis medication. Phenytoin is available intravenously (IV) and because of
its high (80-90%) bioavailability, can be given orally (PO) as well. [51] The drug enters the brain
rapidly and is redistributed throughout the body, being disbursed well throughout all tissues.
[52] Phenytoin has a complex, and not yet fully understood, mechanism of action. It appears
that the primary site of action for phenytoin is the motor cortex, where it inhibits the spread
of seizure activity. Phenytoin has been observed to promote sodium efflux from neurons,
stabilizing the neuron and increasing the cell’s threshold against hyperexcitability caused by
excessive stimulation or environmental changes capable of reducing membrane sodium
gradient. [53] Phenytoin is complex kinetically, saturating its metabolism at clinically utilized
Traumatic Brain Injury174
dosing ranges. Consequently, small changes in dose can translate to large changes in plasma
concentration, potentially leading to toxicity or loss of efficacy. Extensively bound to albumin,
phenytoin plasma levels must be interpreted in the context of the patient’s serum albumin
concentration and if necessary, corrected for. Phenytoin levels are appropriately drawn as a
“trough”, approximately 30 minutes prior administering a dose and the optimal concentration
maximizing efficacy and minimizing toxicity is between 10-20mcg/mL. [53]
The impact of phenytoin on the occurrence of PTS has been investigated repeatedly with
variable results depending on trial design and outcome assessed. Wohns and Wyler investi‐
gated the effect of phenytoin for PTS prophylaxis as compared to no treatment in the seriesz
in 62 patients with severe head injury. The dosing of phenytoin was not standardized, but most
patients received a 1g load with a maintenance dose of 400mg/day. Therapy was continued
for 1 year in the 50 patients managed with phenytoin and plasma concentrations were
maintained between 10-20mcg/mL. There were no early PTS observed in this series but a
marked difference in the incidence of late PTS was observed. Of the 50 patients treated with
phenytoin for seizure prophylaxis, 10% had EEG confirmed late PTS, while those without
prophylaxis experience late PTS at a rate of 50%. There was no statistical assessment of this
data, but the authors hypothesized that phenytoin may offer some degree of protection from
late PTS. [54]
Young et al was not able to confirm the findings of Wohns and Wyler. In a study assessing the
effectiveness of phenytoin prophylaxis in preventing late PTS, patients at high risk (>15%) of
developing late PTS were assigned to receive either PTS prophylaxis with phenytoin or
matching placebo for a minimum of 18 months. There was no measurable difference in the rate
of late PTS between groups, however; all patients in the phenytoin arm whom developed PTS
had plasma concentrations <12mcg/mL, potentially explaining the lack of efficacy. [55]
The landmark trial demonstrating the efficacy of phenytoin in PTS prophylaxis was published
by Temkin et al in 1999. Patients with severe TBI were randomized to receive phenytoin or
placebo for 12 months unless adverse drug reactions necessitated early discontinuation. Those
receiving phenytoin were loaded with 20mg/kg via IV infusion within 24 hours of injury. The
follow-up dosing was not standardized, but an unblinded study-staff member followed
frequent blood levels and adjusted phenytoin dosing as need to maintain high therapeutic
serum concentrations. The effect of phenytoin on both early and late PTS was evaluated as
patients were followed for a total of 24 months (12 months post discontinuation of study
medication). Early PTS occurred at a rate of 3.6% ± 1.3 in those receiving phenytoin versus
14.6% ± 2.6 in the placebo group (p<0.001). This effect was seen in spite of early serum
phenytoin concentrations being less than desired. Unfortunately, the rate of late PTS was
unaffected by phenytoin therapy with no significant difference in the number of PTS events
when compared with placebo after both 1 year (21.2% ± 3.6 vs. 15.7% ± 3.2; p>0.2) and 2 years
(27.5% ± 4 vs. 21.%1 ± 3.7; p>0.2) of treatment. No difference in mortality was observed and
treatment was generally well tolerated, although more patients in the phenytoin group needed
to therapy discontinued secondary to medication related adverse events. [56]
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A follow-up study, looking at the same data set, attempted to determine if PTS prophylaxis
with phenytoin following TBI had any effect on neurocognitive and psychosocial recovery.
All patients, independent of treatment arm, (phenytoin or placebo for 1y post TBI) received
neuropsychological and psychosocial testing 1, 12, and 24 months post injury. Interestingly,
at 1 month post injury, those treated with phenytoin performed significantly worse than those
receiving placebo across most neuropsychological parameters. The difference seemed to
vanish at the 1 year assessment, but it was noted that at the 2 year assessment, there was a
small but widespread negative effect seen in patients treated with phenytoin. Additionally,
the negative trend was also seen in patients receiving placebo that developed PTS and were
subsequently started on phenytoin for the remainder of the study period. [57]
The above mentioned data set was utilized a third time in order to assess if treatment with
phenytoin for 1 or 2 weeks as prophylaxis of early PTS was associated with changes in mortality
or morbidity due to adverse drug events. Rash was the most commonly observed drug
reaction. Hypersensitivity was rarely seen, occurring only in 0.6% of patients during the first
week of therapy and increasing to 2.5% at the end of the second week. Of note, very few adverse
reactions were reported in the first week of therapy, with no reports of fever and only one
report of leukocytosis. No difference in mortality was observed between patients receiving
phenytoin and those receiving placebo, but it was noted that if the patient experienced early
PTS, the risk of death increased significantly independent of the treatment arm (p=0.03 RR 2;
95% CI 1.1-3.7). [58] While this may again encourage the use of phenytoin as prophylaxis
against early PTS, it is important to note that the analysis was not powered to assess a mortality
benefit and when corrected for severity of injury, the mortality benefit was no longer observed.
Considering the risk-benefit ratio for 1 week of therapy and considering the two previous
investigations, a recommendation limiting PTS prophylaxis to 7 days post injury was put forth.
Phenytoin, while potentially efficacious as prophylaxis against early PTS, is a potentially toxic
medication. The side-effect profile of this drug is well documented and while these effects are
rarely seen in a 7 day treatment period, they must be none-the-less considered. Severe,
cutaneous hypersensitivity reactions associated with phenytoin are well documented and
potentially life-threatening. [52, 59, 60] Fever, a significant confounder in the critically ill, and
potential cause of secondary neurological injury, is reported frequently as well. [52, 53, 61]
Phenytoin is an inducer of CYP450 and the UGT isozyme system potentially leading to
multiple drug interactions involving absorption, metabolism, and protein binding which may
drastically impact the effect of the drug on physiology. [52, 53] Phenytoin’s enteric absorption
and bioavailability can also be altered when exposed to a food bolus or continuous enteral tube
feeds. [52] Bauer evaluated the impact of continuous tube feeds on phenytoin absorption in 53
neurosurgical patients when administered via enteric route. All patients were found to have
subtherapeutic serum phenytoin concentrations and approximately 60% continued to be
subtherapeutic even after dosage increase. He notes that hypermetabolism and binding of drug
to tubing were unlikely as symptoms of phenytoin toxicity were observed following discon‐
tinuation of tube feed. [62] In response to these findings, the investigator held tube feedings
for 2 hours prior to and following phenytoin administration and flushed the feeding tube with
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60mL of water before restarting. With this intervention, serum phenytoin concentrations
became therapeutic with only slight dosage increases. [62] Currently, this practice is widely
implemented but also leads to significant nutritional issues. [63] With phenytoin typically
requiring thrice daily dosing, continuous tube feeds could potentially be held for 12 hours
daily. This strategy is met with much resistance as appropriate nutrition may be significantly
hindered.
Fosphenytoin (Cerebyx) was approved by the Food and Drug Administration in 1996 as a
potential replacement for phenytoin. Fosphenytoin is a pro-drug, fully converting via phos‐
phatases in the liver, red blood cells, and tissue, to phenytoin within 20 minutes of adminis‐
tration. The most clinically significant benefit of fosphenytoin is the ability to infuse the
medication as a more rapid rate. Phenytoin loading is often limited by the risk of extravasation
and cardiovascular collapse (hypotenion, bradycardia) and due to these concerns, can only be
infused at a maximum rate of 50mg/ min. Dosed in phenytoin equivalents (PE), the use of
fosphenytoin allows for faster infusion (100-150mg PE/min) and IM administration when there
is a lack of effective IV access. [79]
Due to the above mentioned concerns, much effort has been invested in finding an efficacious
treatment alternative to phenytoin. The drug most commonly utilized in place of phenytoin is
levetiracetam. Levetiracetam is available in both IV and PO formulations with equal bioavail‐
ability. Enteral absorption is rapid and predictable, with peak plasma concentrations occurring
less than 1 hour following administration. Levetiracetam does not undergo any significant
metabolism, avoiding the CYP system which drastically reduces the incidence of clinically
relevant drug interactions. Levetiracetam is excreted primarily by the kidney and dosage
reductions are recommended in patients with significant renal impairment. [64] Levetirace‐
tam’s mechanism of action is poorly understood, but it is thought that it may be novel in its
activity. Animal data seems to suggest that levetiracetam may be protective against the
development of epilepsy in certain clinical scenarios, yet this is unproven in human subjects.
[52, 64, 65] Levetiracetam is very well tolerated and is associated with very few adverse drug
events; however, in several patient populations, levetiracetam has been noted to induce non-
psychotic behavioral disorders and mood instability. [64] Serum levetiracetam concentrations
are not affected by enteric feeds and serum drug level monitoring is not recommended
although there are some reports of increased clearance in TBI patients. [66, 67]
The first published trial assessing the use of levetiracetam for PTS was published by Jones et
al in 2008. In this analysis, 32 patients with severe TBI (GCS 3-8) were given levetiracetam as
PTS prophylaxis at a dosage of 500mg IV every 12 hours for the first 7 days following injury.
These patients were compared with a historical control of 41 patients with similar injuries. If
a clinical seizure was suspected, an EEG was performed and was subsequently interpreted by
a blinded neurologist. The EEG results were classified as normal or abnormal, with abnormal
being further stratified into status epilepticus, seizure, or seizure tendency. The patients
receiving levetiracetam for prophylaxis had 15 EEG examinations with 53% being abnormal.
Seizure activity was only seen in 1 patient, while seizure tendency was observed in the 7 other
abnormal EEG’s. Of the 41 patients receiving phenytoin for prophylaxis, 12 required EEG and
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of those 12, none were considered abnormal. The results of this small, non-randomized
investigation led the authors to conclude that levetiracetam was as effective as phenytoin in
prevention of early PTS. They noted that the observed trend of an increase in seizure tendency
required further investigation. [61]
Szalflarski at al completed a prospective, randomized, placebo controlled trial investigating
the use of levetiracetam versus phenytoin for PTS prophylaxis. Patients with subarachnoid
hemorrhage (SAH) or TBI were randomized in a 2:1 ratio to receive levetiracetam or phenytoin
for 7 days following injury. Levetiracetam was loaded at 20mg/kg followed by 1000mg IV q12
hours. Phenytoin was also loaded, followed by twice daily maintenance dosing but no mention
of desired blood level or strategy of dose adjustment was noted. Patients were placed on
continuous EEG monitoring until awake and following commands or for a maximum of 72
hours. Of the 52 patients enrolled, 34 received levetiracetam while 18 were managed with
phenytoin. No difference was observed in the incidence of seizure or overall mortality.
Phenytoin use was associated with an increase in the incidence of neurological status decline
and gastrointestinal upset while those treated with levetiracetam were devoid of significant
adverse drug reactions. In surviving patients, those treated with levetiracetam had signifi‐
cantly better functional outcomes via GOS and the Disability Rating Scale (DRS) at both 3 and
6 months. [68]
The largest investigation to date comparing levetiracetam to phenytoin for early PTS prophy‐
laxis enrolled 813 patients with severe TBI secondary to blunt impact trauma. At the discretion
of the providing physician, patients received levetiracetam at a dose of 1g every 12 hours or
phenytoin titrated to a serum level of 10-20mcg/mL. No significant difference in the rate of
clinical seizures was noted between groups, nor any difference in adverse drug reactions,
complications of therapy, or mortality. More patients had therapy discontinue due to medi‐
cation side effects in the phenytoin group; however, hospital length of stay was increased in
the levetiracetam group. [69]
With neither therapy providing a distinct advantage in several individual clinical trials, Zafar
at al conducted a meta-analysis attempting to identify any difference in early PTS incidence
when levetiracetam or phenytoin were used for prophylaxis. Eight studies (6 observational/ 2
randomized controlled trials) were included, leading to a total patient population of 990. There
was a trend toward increased efficacy with levetiracetam, but this difference did not reach
statistical significance even when corrected for heterogeneity. It was noted that levetiracetam
may have a more favorable side effect profile, but this meta-analysis was not designed to
formally assess adverse drug events. As no difference in efficacy was noted, the authors
conclude that cost should be the driving factor in the choice of agent for PTS prophylaxis. [70]
A cost-utility analysis by Cotton et al attempted to determine whether levetiracetam or
phenytoin was more cost effective as an early PTS prophylaxis strategy. Using quality-adjusted
life years (QALY) as the primary cost-utility determinant, phenytoin was found to be the more
cost- effective management strategy. Phenytoin was reported to have a ratio of $1.58/ QALY
versus levetiracetam which had a ratio of $20.72/QALY. It must be noted that at the time of
this analysis, levetiracetam was not available as a generic product. Levetiracetam has been
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available via several generic manufactures since May 2010 and the subsequent cost reduction
must be taken in consideration when interpreting these results. [71]
Several other treatment modalities have been investigated as preventive strategies for PTS with
little benefit derived. Valproate was compared with phenytoin for prevention of PTS in high
risk TBI patients. No difference in the incidence of either early or late PTS was noted, but
mortality in the valproate group (13.4%) was almost double that seen in those managed with
phenytoin (7.2%) leading to the early closure of the investigation. [72] Phenobarbital has been
assessed both alone and in combination with phenytoin as a PTS prophylaxis strategy. When
used as monotherapy for PTS prophylaxis in severe head injury, no benefit was observed and,
due to adverse drug reactions, medication compliance was poor. [73] In combination with
phenytoin, there was an observed reduction in seizures, but this difference could have been
influenced by the use of phenytoin, and significant concern of toxicity was noted. [74]
Magnesium was thought to be potentially neuroprotective, but when higher serum concen‐
trations were targeted with continuous infusion there was an increase in the incidence of
hypotension, reduced cerebral perfusion pressure, and a doubling of mortality. Lower
magnesium target ranges also failed to provide any benefit. [75] In an observational series,
corticosteroids were found to provide no PTS protection and were found to worsen excito‐
toxicity and oxidative neuronal damage in animal models. [76] There is a theoretic benefit with
targeted temperature management as this therapy has several neuroprotective effects such as
reduced metabolic rate, reduced inflammatory response, fewer epileptic discharges, and a
reduction in the production of reactive oxygen species. This modality has not been formally
evaluated for its impact on PTS, but offers a potential area of future research and potential
benefit. [77]
As of 2007, the Brain Trauma Foundation guidelines for the management of severe traumatic
brain injury consider the use of anti-epileptic medications for early PTS prophylaxis a Level II
recommendation and note that prolonged prophylactic therapy (>7days) is not recommended.
At the time of publication, phenytoin was the preferred agent for early PTS prophylaxis, but
in the time since, a significant amount data surrounding the use of levetiracetam has been
published. At this point, the two therapies should be considered equivalent from an efficacy
standpoint, but consideration needs to be given to the individual characteristics of each
medication and institutional costs associated with their administration. [78]
Traumatic brain injury is a devastating disorder having significant impact on patient morbidity
and mortality. Seizures following TBI are a potentially preventable complication if the patients
at highest risk are identified quickly and are initiated on a prophylactic regimen. The highest
risk patients (penetrating injury, age <16, GCS <10, basilar skull fracture, intracerebral blood)
should be started on prophylactic anticonvulsant therapy as soon as possible. Based on the
latest evidence, there are two potentially efficacious strategies; phenytoin (or substituted
fosphenytoin) and levetiracetam. Phenytoin appears most effective when loaded at a dosage
of 10-15mg/kg followed by a regimen of 100mg every 8 hours and should be titrated to a trough
total phenytoin concentration of 10-20 mcg/mL. Levetiracetam is an acceptable alternative
regimen found to be effective when dosed at 1000mg every 12 hours with no serum drug
monitoring being currently recommended. Both phenytoin and levetiracetam should be
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administered for 7 days following initial injury and when utilized in this manner a significant
reduction in early PTS is observed, potentially improving patient outcomes.
Drug Name (Brand) Phenytoin (Dilantin) Levetiracetam (Keppra)
Mechanism of Action Enhanced sodium efflux from neurons of
the motor cortex, stabilizing the
threshold against hyperexcitability.
Posttetanic potentiation at synapses is
then reduced preventing cortical seizure
foci from detonating adjacent cortical
areas
Inhibition of voltage-dependent N-type
calcium channels; facilitation of GABA-ergic
inhibitory transmission; reduction of delayed
rectifier potassium current; and/or binding to
synaptic proteins which modulate
neurotransmitter release
Route of Administration IV/ PO IV/ PO
Typical Loading Dose 10-15mg/kg x1 None recommended
Fosphenytoin: 10-20mg PE/kg
Typical Maintenance Dose 100mg q8hr 500-1000mg q12hr
Fosphenytoin: 4-6mg PE/kg
Elimination Half-Life 7-42 hours 6-8 hours
(Metabolite =8.4 hr)
Metabolism/ Excretion Metabolism: Hepatic via hydroxylation Metabolism: enzymatic hydrolysis via liver
Excretion: Extensively excreted in bile as
well as in urine following gastrointestinal
reabsorption
Excretion: 66% unchanged in urine
Dosing Considerations Metabolism and excretion may be
impaired in renal and hepatic disease.
Consider following unbound phenytoin
levels for dose adjustment
Consider dosage reduction in patients with
renal failure
Major Adverse Effects Rash Pancytopenia
Nausea/ vomiting Thrombocytopenia
Ataxia Liver Failure
Confusion Personality disturbances
Fever
Stevens-Johnson Syndrome
Myelosuppression
Nephrotoxicity
Hypotension
Bradycardia
Venous irritation
Monitoring/ Laboratory
Considerations
Monitor trough concentration for
efficacy. Toxicity is a clinical diagnosis and
must be assess based on patient
No routine monitoring currently
recommended
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Drug Name (Brand) Phenytoin (Dilantin) Levetiracetam (Keppra)
presentation. At times, patients may
require blood concentrations outside
therapeutic range
If rapid therapeutic levels are needed, a
level may be drawn 2 hrs after
completion of IV load or 24 hrs after
administration of an oral loading dose
Draw within 5-8 days of therapy initiation
with subsequent doses of phenytoin
adjusted accordingly
If complex patient free phenytoin
concentration is desirable
Goal concentration 10-20 mcg/ml (Total)
1-2.5mcg/mL (Free)
In patients with hypoalbuminemia,
phenytoin concentration needs to be
corrected mathematically or free level
should be drawn
CORRECTED PHENYTOIN= (Measured
Phenytoin) 0.1 x Albumin +0.1
Table 3. makinji caption
Author details
Matthew J.  Korobey
Mercy Hospital St. Louis, St. Louis MO, USA
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